{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:48:46Z","timestamp":1780058926084,"version":"3.54.0"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) are critical in the modern treatment of advanced melanoma but can provoke immune-related adverse events (irAEs) with increased risk in patients having pre-existing autoimmune conditions. We present a case of Felty syndrome (FS) recurrence precipitated by a single dose of combination nivolumab plus relatlimab immunotherapy in a 71-year-old man with metastatic melanoma and a history of seropositive rheumatoid arthritis (RA) diagnosed several years earlier in the context of spontaneous FS. Following ICI, he presented with a neutrophil count of 0.0 cells\/\u00b5L but without clinically active synovitis. He was promptly managed with intravenous methylprednisolone and methotrexate with rapid neutrophil recovery despite the ICI precipitant. In this report, we explore the differential diagnoses and treatment considerations, which highlight the importance of considering ICI-induced FS as a differential diagnosis in patients with a history of RA presenting with neutropenia. Early identification and collaborative care are vital for preventing life-threatening complications associated with neutropenia in this vulnerable patient population.<\/jats:p>","DOI":"10.3389\/fonc.2026.1808710","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:13:29Z","timestamp":1776658409000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Immunotherapy-induced Felty syndrome in a patient with metastatic melanoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Laura S.","family":"Park","sequence":"first","affiliation":[{"name":"Medical Oncology, Alfred Health","place":["Melbourne, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caoimhe","family":"Byrne","sequence":"additional","affiliation":[{"name":"Medical Oncology, Alfred Health","place":["Melbourne, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Burridge","sequence":"additional","affiliation":[{"name":"Medical Oncology, Alfred Health","place":["Melbourne, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Monash Health","place":["Clayton, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Leech","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Monash Health","place":["Clayton, VIC, Australia"]},{"name":"Faculty of Medicine Nursing and Health Sciences, Monash University","place":["Clayton, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles C.","family":"Andrews","sequence":"additional","affiliation":[{"name":"Medical Oncology, Alfred Health","place":["Melbourne, VIC, Australia"]},{"name":"Department of Cancer Medicine, School of Translational Medicine, Monash University","place":["Melbourne, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s41927-022-00297-5","article-title":"Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy","volume":"6","author":"Lusa","year":"2022","journal-title":"BMC Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.41.5.486","article-title":"Long-term outcome in Felty's syndrome","volume":"41","author":"Thorne","year":"1982","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2139\/ssrn.4257624","article-title":"Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis","volume":"188","author":"Boutros","year":"2023","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2174\/1874312901408010129","article-title":"Felty's syndrome, insights and updates","volume":"8","author":"Owlia","year":"2014","journal-title":"Open Rheumatol J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytab342","article-title":"A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil","volume":"5","author":"Jespersen","year":"2021","journal-title":"Eur Heart J Case Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45674","article-title":"Isolated neutropenia due to immune checkpoint inhibitors","volume":"15","author":"Jalil","year":"2023","journal-title":"Cureus"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases","volume":"18","author":"Tison","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: A practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1808710\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:13:32Z","timestamp":1776658412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1808710\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":11,"alternative-id":["10.3389\/fonc.2026.1808710"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1808710","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"article-number":"1808710"}}